
Leukemia vaccine passes key trial, adding to breakthrough year for cancer drugs
A first-of-its-kind vaccine for acute myeloid leukemia, a deadly blood cancer, has successfully completed a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced Tuesday, marking another positive result in a groundbreaking year for cancer vaccines.
Gn bussni